Live Breaking News & Updates on Ebitda Al|Page 9

Stay updated with breaking news from Ebitda al. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Tata Play: Broadband, OTT may keep Tata Play in good stead amid DTH dip

Tata Play s revenue from its core direct-to-home (DTH) business is expected to decline in the medium term due to a slowdown in its subscriber base. However, this decrease is anticipated to be balanced by growth in broadband and over-the-top (OTT) businesses. Operating margins may face pressure in FY24 and FY25 due to the subscriber base moderation, although partly offset by improved metrics from Tata Play Binge and expected breakeven from Tata Play Broadband. ....

Walt Disney , Tata Play , Tata Play Binge , Tata Play Broadband , Tata Sons ,

TVS Motor Company Posts Highest Ever Revenue, EBITDA and Profit in Q2

TVS Motor Company Posts Highest Ever Revenue, EBITDA and Profit in Q2 : Rashtra News TVS Motor Company’s operating revenue grew by 28% at Rs. 7,219 Crores for the quarter ended September 2022 as against Rs. 5,619 Crores reported in the quarter ended September 2021. The Company’s Operating EBITDA grew by 31% at Rs. ....

Tamil Nadu , Himachal Pradesh , United Kingdom , Jawa Barat , Tvs Motor Company Posts Highest Ever Revenue , Company Operating , Jd Power Customer Service Satisfaction , Motor Company , Company Profit Before Tax , Swiss Group , Company Posts Highest Ever Revenue , Profit Before Tax , Profit After Tax , Qube Electric , Sustainable Mobility , Customer Service Satisfaction Survey , Norton Motorcycles , Swisse Mobility Group , Half Year Results , New Product Launches , Tvs Motor Company ,

Piramal Pharma: Fundamental Radar: Why does Piramal Pharma stock deserve a re-rating? Sandeep Raina explains

The company witnessed multiple challenges related to macroeconomic factors during and after COVID-19, high attrition at European manufacturing sites, dismal biotech funding, and cost escalation, which left most of the CDMO assets underutilized during FY22-23. ....

Piramal Pharma , Suven Pharma , Sandeep Raina , Gland Pharma ,